| Literature DB >> 27336050 |
Jingxia Lin1, Sherry Kw Chan1, Edwin Hm Lee1, Wing Chung Chang1, Michael Tse2, Wayne Weizhong Su3, Pak Sham1, Christy Lm Hui1, Glen Joe2, Cecilia Lw Chan4, P L Khong5, Kwok Fai So6, William G Honer3, Eric Yh Chen1.
Abstract
Impairments of attention and memory are evident in early psychosis, and are associated with functional disability. In a group of stable, medicated women patients, we aimed to determine whether participating in aerobic exercise or yoga improved cognitive impairments and clinical symptoms. A total of 140 female patients were recruited, and 124 received the allocated intervention in a randomized controlled study of 12 weeks of yoga or aerobic exercise compared with a waitlist group. The primary outcomes were cognitive functions including memory and attention. Secondary outcome measures were the severity of psychotic and depressive symptoms, and hippocampal volume. Data from 124 patients were included in the final analysis based on the intention-to-treat principle. Both yoga and aerobic exercise groups demonstrated significant improvements in working memory (P<0.01) with moderate to large effect sizes compared with the waitlist control group. The yoga group showed additional benefits in verbal acquisition (P<0.01) and attention (P=0.01). Both types of exercise improved overall and depressive symptoms (all P⩽0.01) after 12 weeks. Small increases in hippocampal volume were observed in the aerobic exercise group compared with waitlist (P=0.01). Both types of exercise improved working memory in early psychosis patients, with yoga having a larger effect on verbal acquisition and attention than aerobic exercise. The application of yoga and aerobic exercise as adjunctive treatments for early psychosis merits serious consideration. This study was supported by the Small Research Funding of the University of Hong Kong (201007176229), and RGC funding (C00240/762412) by the Authority of Research, Hong Kong.Entities:
Year: 2015 PMID: 27336050 PMCID: PMC4849465 DOI: 10.1038/npjschz.2015.47
Source DB: PubMed Journal: NPJ Schizophr ISSN: 2334-265X
Figure 1Flow chart of patients through study. IIT, intention to treat.
Figure 2Mean cognitive scores and symptom values for patients in the three groups, according to yhe HKLLT, Digit Span Backwards Test, Letter Cancellation Test and PANSS total scores at baseline and 12 weeks for verbal acquisition (a), working memory (b), attention (c), and symptom severity (d).
Measures of cognition, clinical symptoms, quality of life, and hippocampal volume at baseline, after 12 weeks intervention and at 18-month follow-up
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
|
| |||||||||
| Sample size | 45 | 38 | 23 | 40 | 31 | 22 | 39 | 33 | 18 |
| HKLLT-acquisition, mean (s.d.) | 23.4 (6.1) | 30.1 (6.6) | 28.1 (6.3) | 22.7 (8.0) | 29.1 (8.2) | 28.9 (8.2) | 22.7 (7.6) | 24.7 (8.1) | 29.6 (6.7) |
| HKLLT-retention, mean (s.d.) | 15.2 (6.1) | 19.8 (6.0) | 18.4 (6.5) | 15.6 (5.4) | 21.3 (7.1) | 19.6 (7.5) | 14.5 (7.0) | 16.5 (7.2) | 19.1 (6.9) |
| Digit span forwards test, mean (s.d.) | 11.7 (2.3) | 12.7 (1.8) | 12.4 (2.0) | 12.1 (1.8) | 13.1 (1.2) | 12.8 (1.1) | 12.3 (1.8) | 12.3 (2.1) | 13.4 (0.9) |
| Digit span backwards test, mean (s.d.) | 7.0 (3.0) | 8.7 (3.0) | 8.5 (3.4) | 6.7 (2.5) | 9.5 (3.0) | 9.4 (3.3) | 7.7 (3.3) | 7.3 (2.7) | 9.2 (3.0) |
| Letter cancellation test, Q score, mean (s.d.) | 0.76 (0.14) | 0.85 (0.18) | 0.82 (0.15) | 0.72 (0.21) | 0.78 (0.19) | 0.79 (0.21) | 0.75 (0.15) | 0.73 (0.17) | 0.84 (0.13) |
| Stroop test congruent condition, correct items mean (s.d.) | 110.3 (2.6) | 111.1 (1.8) | 110.9 (1.1) | 110.0 (2.7) | 110.9 (2.5) | 110.6 (1.7) | 110.5 (1.6) | 110.4 (1.5) | 111.4 (1.0) |
| Stroop test incongruent condition, corrected items, mean (s.d.) | 105.7 (4.5) | 108.2 (3.4) | 108.8 (3.3) | 105.4 (5.6) | 106.9 (4.6) | 107.5 (3.6) | 103.3 (8.2) | 105.5 (6.1) | 108.7 (2.8) |
|
| |||||||||
| Sample size | 45 | 38 | 23 | 40 | 31 | 22 | 39 | 33 | 18 |
| PANSS total, mean (s.d.) | 47.5 (15.4) | 37.6 (9.3) | 39.1 (9.7) | 46.4 (15.9) | 39.1 (10.9) | 35.6 (6.3) | 45.9 (15.3) | 49.4 (15.8) | 42.2 (10.7) |
| PANSS positive, mean (s.d.) | 10.2 (3.7) | 8.7 (2.7) | 8.6 (2.2) | 9.5 (4.5) | 8.3 (2.4) | 7.8 (1.5) | 9.9 (3.8) | 10.1 (3.5) | 9.9 (4.4) |
| PANSS negative, mean (s.d.) | 10.8 (4.2) | 8.5 (2.7) | 8.4 (3.1) | 10.9 (5.6) | 9.5 (3.7) | 8.1 (2.1) | 11.2 (4.1) | 12.7 (5.1) | 9.6 (3.8) |
| PANSS general, mean (s.d.) | 26.6 (9.3) | 20.4 (5.5) | 22.1 (7.0) | 26.0 (9.2) | 21.3 (6.7) | 19.6 (3.9) | 24.8 (9.2) | 26.6 (9.6) | 22.7 (5.2) |
| CDS total, mean (s.d.) | 4.1 (4.2) | 1.7 (2.4) | 2.7 (3.4) | 3.3 (4.0) | 1.6 (2.3) | 1.7 (1.9) | 3.7 (4.7) | 4.3 (4.3) | 1.8 (1.7) |
|
| |||||||||
| Sample size | 25 | 20 | 28 | 17 | 20 | 13 | |||
| Left HPC, mean (s.d.) | 3,511 (290) | 3,459 (259) | 3,461 (385) | 3,475 (428) | 3,533 (314) | 3,530 (272) | |||
| Right HPC, mean (s.d.) | 3,726 (309) | 3,667 (262) | 3,645 (373) | 3,638 (378) | 3,726 (326) | 3,724 (310) | |||
| Total HPC, mean (s.d.) | 7,237 (589) | 7,126 (506) | 7,106 (741) | 7,113 (793) | 7,259 (629) | 7,254 (560) | |||
|
| |||||||||
| Sample size | 44 | 38 | 40 | 31 | 38 | 32 | |||
| Physical health, mean (s.d.) | 64.1 (16.9) | 71.4 (18.0) | 64.5 (17.2) | 75.0 (17.4) | 69.4 (17.4) | 68.8 (19.5) | |||
| Psychological health, mean (s.d.) | 57.2 (22.0) | 67.8 (21.6) | 60.0 (19.2) | 73.1 (29.6) | 60.7 (20.0) | 57.2 (23.6) | |||
|
| |||||||||
| Sample size | 44 | 38 | 23 | 40 | 31 | 22 | 38 | 32 | 18 |
| FRS, mean (s.d.) | 1.8 (1.2) | 1.8 (1.4) | 2.0 (1.1) | 1.5 (1.0) | 1.5 (1.2) | 1.6 (1.3) | 1.6 (1.4) | 1.3 (1.3) | 1.5 (1.3) |
|
| |||||||||
| Sample size | 41 | 37 | 23 | 37 | 31 | 22 | 35 | 32 | 18 |
| MCR, mean (s.d.) | 6.0 (0.7) | 6.0 (0.5) | 5.9 (0.4) | 5.9 (0.8) | 6.1 (0.7) | 6.0 (0.8) | 5.9 (0.5) | 6.0 (0.7) | 5.9 (0.3) |
|
| |||||||||
| Sample size | 38 | 23 | 35 | 18 | 23 | 11 | |||
| VO2 max | 25.3 (6.2) | 25.9 (5.5) | 27.1 (5.4) | 29.2 (5.9) | 26.1 (5.0) | 26.0 (5.2) | |||
Abbreviations: CDS, calgary depression scale; FRS, figure rating scale; HKLLT, Hong Kong list learning test; HPC, hippocampus; MCR, medication compliance rating; PANSS, positive and negative syndrome scale.
Statistical significance and associated effect sizes of comparisons within and between the groups over 12 weeksa
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| |||
| Verbal acquisition | 37.24 | <0.010 | 10.81 | <0.010 | 0.97 | 21.19 | <0.010 | 5.72 | 0.020 | 0.83 |
| Verbal retention | 37.81 | <0.010 | 5.22 | .026 | 0.40 | 29.41 | <0.010 | 6.20 | 0.016 | 0.56 |
| DS forwards test | 5.71 | 0.020 | 9.56 | <0.010 | 0.77 | 2.65 | 0.109 | 6.43 | 0.014 | 0.59 |
| DS backwards test | 2.79 | 0.100 | 10.75 | <0.010 | 0.71 | 13.60 | <0.010 | 30.82 | <0.010 | 1.08 |
| LC Q score | 3.86 | 0.054 | 7.45 | <0.010 | 0.69 | 1.08 | 0.303 | 3.13 | 0.082 | 0.22 |
| Stroop test congruent condition, correct items | 1.81 | 0.183 | 2.00 | 0.162 | 0.34 | 0.90 | 0.347 | 0.89 | 0.349 | 0.30 |
| Stroop test incongruent condition, correct items | 8.50 | <0.010 | 0.28 | 0.597 | 0.12 | 4.61 | 0.035 | 1.13 | 0.292 | 0.36 |
| PANSS total | 1.02 | 0.316 | 11.87 | <0.010 | 1.54 | 0.11 | 0.747 | 6.76 | 0.012 | 1.14 |
| PANSS positive | 0.87 | 0.354 | 2.80 | 0.099 | 0.51 | 0.88 | 0.351 | 3.37 | 0.071 | 0.29 |
| PANSS negative | 0.04 | 0.838 | 11.70 | <0.010 | 0.91 | 0.75 | 0.392 | 3.50 | 0.067 | 0.61 |
| PANSS general | 1.36 | 0.249 | 11.09 | <0.010 | 0.95 | 0.35 | 0.556 | 6.63 | 0.013 | 0.32 |
| CDS total | 0.58 | 0.451 | 10.38 | <0.010 | 0.74 | 0.38 | 0.538 | 8.79 | <0.010 | 0.58 |
| QoL (physical health) | 0.91 | 0.343 | 6.21 | 0.015 | 0.46 | 4.35 | 0.042 | 15.52 | <0.010 | 0.62 |
| QoL (psychological health) | 0.95 | 0.333 | 9.37 | <0.010 | 0.65 | 1.29 | 0.261 | 6.36 | 0.015 | 0.73 |
| Body perception (FRS) | 1.69 | 0.198 | 1.14 | 0.288 | 0.37 | 2.43 | 0.124 | 0.32 | 0.577 | 0.23 |
| Drug adherence (CRS) | 0.08 | 0.786 | 0.41 | 0.525 | 0.21 | 1.30 | 0.259 | 0.06 | 0.816 | 0.13 |
| VO2 max | 0.25 | 0.624 | 0.12 | 0.729 | 0.24 | 4.08 | 0.054 | 0.35 | 0.560 | 0.22 |
Abbreviations: CDS, calgary depression scale; CRS, compliance rating scale; DS, digit span test; ES, effect size; FRS, figure rating scale; LC, letter cancellation test; PANSS, positive and negative syndrome scale; QoL, quality of life.
P values represent the statistical significance of the effect of time and of the Group×Time interaction in a mixed model in unstructured variance matrix. Age, education years, length of illness, and antipsychotic dose were included as covariates for cognitive data analysis, and age, length of illness and antipsychotic dose were included as covariates for clinical data analysis.
Assessments used at baseline and 12 weeks
|
| ||
|---|---|---|
| Physical fitness | VO2 max test | Maximum capacity of an individual’s body to transport and utilize oxygen during incremental exercise. |
| Cognitive function | Hong Kong list learning test (HKLLT) | Verbal memory |
| Digit span test | Working memory | |
| Letter cancellation test | Attention | |
| Stroop color and word tests | Executive function | |
| Clinical symptoms | Positive and negative syndrome scale (PANSS) | Clinical symptoms |
| Calgary depression scale (CDS) | Depressive symptoms for schizophrenia | |
| Brain structures | Structural magnetic resonance imaging (MRI) | — |
| Body perception | Figure rating scale (FRS) | — |
| Medication adherence | Compliance rating scale (CRS) | — |
| Quality of life | The short form (36) health survey (SF-36) | — |
Demographic information for subjects participating in the study
|
| |||
|---|---|---|---|
|
|
|
| |
|
| |||
|
| 23.8 (6.8) | 24.6 (7.9) | 25.3 (8.1) |
|
| 12.0 (2.1) | 13.1 (3.3) | 12.2 (2.6) |
|
| 2.5 (2.1) | 2.4 (2.0) | 2.0 (2.0) |
|
| |||
|
| 42 (93.3) | 35 (87.5) | 38 (97.4) |
|
| 0 | 1 (2.5) | 0 |
|
| 3 (6.7) | 4 (10.0) | 1 (2.6) |
|
| |||
|
| 45 (100) | 40 (100) | 39 (100) |
|
| 0 | 0 | 0 |
|
| |||
|
| 21 (47.7) | 20 (50.0) | 19 (50.0) |
|
| 4 (9.1) | 6 (15.0) | 3 (7.9) |
|
| 0 | 1 (2.5) | 0 |
|
| 2 (4.5) | 3 (7.5) | 0 |
|
| 16 (36.4) | 8 (20.0) | 15 (39.5) |
|
| 1 (2.2) | 2 (5.0) | 1 (2.6) |
|
| 339 (263) | 288 (240) | 260 (211) |
|
| |||
| | |||
|
| 0 | 0 | 1 (2.9) |
|
| 0 | 0 | 1 (2.9) |
|
| 2 (4.4) | 1 (2.6) | 0 |
|
| 0 | 0 | 1 (2.9) |
|
| 2 (4.4) | 0 | 0 |
| | |||
|
| 3 (7.0) | 3 (7.7) | 0 |
|
| 8 (18.6) | 11 (28.2) | 12 (34.3) |
|
| 11 (25.6) | 7 (17.9) | 6 (17.1) |
|
| 9 (20.9) | 4 (10.3) | 7 (20.0) |
|
| 4 (8.9) | 3 (7.7) | 2 (5.7) |
|
| 0 | 1 (2.6) | 0 |
|
| 3 (7.0) | 8 (20.5) | 5 (14.3) |
|
| 0 | 1 (2.6) | 0 |
| | |||
|
| |||
|
| |||
|
| 47.51 (15.4) | 46.35 (15.9) | 45.87 (15.3) |
|
| 10.2 (3.7) | 9.5 (4.5) | 9.9 (3.8) |
|
| 10.8 (4.2) | 10.9 (5.6) | 11.2 (4.1) |
|
| 26.6 (9.3) | 26.0 (9.2) | 24.8 (9.2) |
| CDS total score | 4.1 (4.2) | 3.3 (4.0) | 3.7 (4.7) |
Abbreviations: CPZ, chlorpromazine; CDS, calgary depression scale; PANSS, positive and negative syndrome scale; y, years.